Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03

AUTHORS

Anne Gardin, Mike Ufer, Eric Legangneux, Gianluca Rossato, Yi Jin, Zhenzhong Su, Parasar Pal, Wenkui Li, Kasra Shakeri-Nejad

ABSTRACT

OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole (Study A), and (2) with three different CYP2C9 genotype variants (Study B). METHODS: Study A was an open-label, single-dose study comprising periods 1 (14 days; day 1: siponimod 4 mg) and 2 (20 days; day 1: fluconazole 200 mg twice daily; days 2-19: fluconazole 200 mg once daily; day 3: siponimod 4 mg) in healthy subjects (n = 14) with the wild-type CYP2C9 genotype (CYP2C9*1/*1). Study B was a multicentre, open-label study comprising parts 1 (day 1: siponimod 0.25 mg once daily in the CYP2C9*1/*1, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes) and 2 (days 1-2: 0.25 mg once daily; day 3: 0.5 mg once daily in the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes only) in healthy subjects with polymorphic variants of CYP2C9 (n = 24). Pharmacokinetic parameters were calculated using noncompartmental methods. RESULTS: In Study A, coadministration with fluconazole produced an approximately twofold increase in mean area under the curve (AUC) versus siponimod alone (from 1110 to 2160 h*ng/mL), and an increase in maximum plasma concentration (Cmax; from 31.2 to 34.0 ng/mL) and elimination half-life (T½; from 40.6 to 61.6 h). In Study B, the AUCs of siponimod were approximately two to fourfold greater in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, with a minor increase in Cmax versus the CYP2C9*1/*1 genotype. The mean T½ was prolonged in the CYP2C9*2/*3 (51 h) and CYP2C9*3/*3 (126 h) genotypes versus the CYP2C9*1/*1 (28 h) genotype. Siponimod did not result in increased adverse events in healthy subjects in both studies. CONCLUSIONS: Changes in siponimod PK, when coadministered with fluconazole at steady-state and in subjects with different CYP2C9 genotypes, indicate that the reduced CYP2C9 enzymatic activity does not affect the absorption phase of siponimod but prolongs the elimination phase. These results confirm the relevance of CYP2C9 activity on siponimod metabolism in humans. More... »

PAGES

349-361

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3

DOI

http://dx.doi.org/10.1007/s40262-018-0700-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106022094

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30088221


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gardin", 
        "givenName": "Anne", 
        "id": "sg:person.0746041340.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ufer", 
        "givenName": "Mike", 
        "id": "sg:person.0614623553.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614623553.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legangneux", 
        "givenName": "Eric", 
        "id": "sg:person.01152111734.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossato", 
        "givenName": "Gianluca", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jin", 
        "givenName": "Yi", 
        "id": "sg:person.0757541121.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757541121.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Beijing Novartis Pharmaceuticals Corporation, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Su", 
        "givenName": "Zhenzhong", 
        "id": "sg:person.015620100105.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015620100105.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt. Ltd, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pal", 
        "givenName": "Parasar", 
        "id": "sg:person.0615427741.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615427741.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Institutes for Biomedical Research, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Wenkui", 
        "id": "sg:person.01314355711.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314355711.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shakeri-Nejad", 
        "givenName": "Kasra", 
        "id": "sg:person.01367544315.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaneurol.2016.1451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011275377"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaneurol.2016.1451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011275377"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.108.020396", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013227922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2008.302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015890832", 
          "https://doi.org/10.1038/clpt.2008.302"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/pgs.10.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020935714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/nyas.12821", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023965742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023978690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/j.clpt.2004.08.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033907987", 
          "https://doi.org/10.1016/j.clpt.2004.08.009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2133/dmpk.dmpk-12-rv-085", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043672512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2015.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047057921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2015.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047057921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/blr.2006.25.447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059238419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-200309000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060290069"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-200309000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060290069"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-200309000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060290069"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/fpc.0b013e3283349e84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060340789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/fpc.0b013e3283349e84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060340789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/fpc.0b013e3283349e84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060340789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082883663", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03", 
    "datePublishedReg": "2019-03-01", 
    "description": "OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole\u00a0(Study A), and (2) with three different CYP2C9 genotype variants\u00a0(Study B).\nMETHODS: Study A was an open-label, single-dose study comprising periods 1 (14\u00a0days; day 1: siponimod 4\u00a0mg) and 2 (20\u00a0days; day 1: fluconazole 200\u00a0mg twice daily; days 2-19: fluconazole 200\u00a0mg once daily; day 3: siponimod 4\u00a0mg) in healthy subjects (n\u2009= 14) with the wild-type CYP2C9 genotype (CYP2C9*1/*1). Study B was a multicentre, open-label study comprising parts 1 (day 1: siponimod 0.25\u00a0mg once daily in the CYP2C9*1/*1, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes) and 2 (days 1-2: 0.25\u00a0mg once daily; day 3: 0.5\u00a0mg once daily in the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes only) in healthy subjects with polymorphic variants of CYP2C9 (n\u2009= 24). Pharmacokinetic parameters were calculated using noncompartmental methods.\nRESULTS: In Study A, coadministration with fluconazole produced an approximately twofold increase in mean area under the curve (AUC) versus siponimod alone (from 1110 to 2160\u00a0h*ng/mL), and an increase in maximum plasma concentration (Cmax; from 31.2 to 34.0\u00a0ng/mL) and elimination half-life (T\u00bd; from 40.6 to 61.6\u00a0h). In Study B, the AUCs of siponimod were approximately two to fourfold greater in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, with a minor increase in Cmax versus the CYP2C9*1/*1 genotype. The mean T\u00bd was prolonged in the CYP2C9*2/*3 (51\u00a0h) and CYP2C9*3/*3 (126\u00a0h) genotypes versus the CYP2C9*1/*1 (28\u00a0h) genotype. Siponimod did not result in increased adverse events in healthy subjects in both studies.\nCONCLUSIONS: Changes in siponimod PK, when coadministered with fluconazole at steady-state and in subjects with different CYP2C9 genotypes, indicate that the reduced CYP2C9 enzymatic activity does not affect the absorption phase of siponimod but prolongs the elimination phase. These results confirm the relevance of CYP2C9 activity on siponimod metabolism in humans.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40262-018-0700-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "58"
      }
    ], 
    "name": "Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects", 
    "pagination": "349-361", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c12c77da7653d5747ef1139b8707361a28985ba0fef3adc5ff96e36faef3a19b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30088221"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7606849"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40262-018-0700-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106022094"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40262-018-0700-3", 
      "https://app.dimensions.ai/details/publication/pub.1106022094"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000354_0000000354/records_11707_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40262-018-0700-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      21 PREDICATES      50 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40262-018-0700-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N2742310cb57b45a1a2f5c5e7c4faff96
4 schema:citation sg:pub.10.1007/s00228-017-2404-2
5 sg:pub.10.1016/j.clpt.2004.08.009
6 sg:pub.10.1038/clpt.2008.302
7 https://app.dimensions.ai/details/publication/pub.1082883663
8 https://doi.org/10.1001/jamaneurol.2016.1451
9 https://doi.org/10.1002/jcph.561
10 https://doi.org/10.1016/j.clinthera.2015.09.006
11 https://doi.org/10.1016/s0140-6736(18)30475-6
12 https://doi.org/10.1016/s1474-4422(13)70102-9
13 https://doi.org/10.1089/blr.2006.25.447
14 https://doi.org/10.1097/00008571-200309000-00005
15 https://doi.org/10.1097/fpc.0b013e3283349e84
16 https://doi.org/10.1111/j.1365-2125.2012.04400.x
17 https://doi.org/10.1111/j.1476-5381.2012.02061.x
18 https://doi.org/10.1111/nyas.12821
19 https://doi.org/10.1124/dmd.108.020396
20 https://doi.org/10.1124/dmd.117.079574
21 https://doi.org/10.2133/dmpk.dmpk-12-rv-085
22 https://doi.org/10.2217/pgs.10.49
23 https://doi.org/10.5414/cp202588
24 https://doi.org/10.5414/cp202608
25 schema:datePublished 2019-03
26 schema:datePublishedReg 2019-03-01
27 schema:description OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole (Study A), and (2) with three different CYP2C9 genotype variants (Study B). METHODS: Study A was an open-label, single-dose study comprising periods 1 (14 days; day 1: siponimod 4 mg) and 2 (20 days; day 1: fluconazole 200 mg twice daily; days 2-19: fluconazole 200 mg once daily; day 3: siponimod 4 mg) in healthy subjects (n = 14) with the wild-type CYP2C9 genotype (CYP2C9*1/*1). Study B was a multicentre, open-label study comprising parts 1 (day 1: siponimod 0.25 mg once daily in the CYP2C9*1/*1, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes) and 2 (days 1-2: 0.25 mg once daily; day 3: 0.5 mg once daily in the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes only) in healthy subjects with polymorphic variants of CYP2C9 (n = 24). Pharmacokinetic parameters were calculated using noncompartmental methods. RESULTS: In Study A, coadministration with fluconazole produced an approximately twofold increase in mean area under the curve (AUC) versus siponimod alone (from 1110 to 2160 h*ng/mL), and an increase in maximum plasma concentration (Cmax; from 31.2 to 34.0 ng/mL) and elimination half-life (T½; from 40.6 to 61.6 h). In Study B, the AUCs of siponimod were approximately two to fourfold greater in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, with a minor increase in Cmax versus the CYP2C9*1/*1 genotype. The mean T½ was prolonged in the CYP2C9*2/*3 (51 h) and CYP2C9*3/*3 (126 h) genotypes versus the CYP2C9*1/*1 (28 h) genotype. Siponimod did not result in increased adverse events in healthy subjects in both studies. CONCLUSIONS: Changes in siponimod PK, when coadministered with fluconazole at steady-state and in subjects with different CYP2C9 genotypes, indicate that the reduced CYP2C9 enzymatic activity does not affect the absorption phase of siponimod but prolongs the elimination phase. These results confirm the relevance of CYP2C9 activity on siponimod metabolism in humans.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N715c2e5fefa64b40b6c8bb791a12cc4b
32 Nbab256c6dadf47ff93146ccec63eddc3
33 sg:journal.1085321
34 schema:name Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
35 schema:pagination 349-361
36 schema:productId N1c7fca4dee36411697f03c684c232eca
37 N1f966d07677a4888a0c2364ecc029f53
38 N5ca8b132547140c99198a9ff14eed769
39 N90e3bcbabaf640348b0551109f9787b1
40 N9365cdad99c144ff8a7263a09dc564ce
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106022094
42 https://doi.org/10.1007/s40262-018-0700-3
43 schema:sdDatePublished 2019-04-11T11:19
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher N9c9a4d81561c4d7bbe03167e6c5d4ed7
46 schema:url https://link.springer.com/10.1007%2Fs40262-018-0700-3
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N033eaeb36fdb44a7bd7ab9a3cec1e6ae rdf:first sg:person.0615427741.32
51 rdf:rest N72a9410337f64f54a41db550d9961b97
52 N1c7fca4dee36411697f03c684c232eca schema:name nlm_unique_id
53 schema:value 7606849
54 rdf:type schema:PropertyValue
55 N1f966d07677a4888a0c2364ecc029f53 schema:name pubmed_id
56 schema:value 30088221
57 rdf:type schema:PropertyValue
58 N21799051d7404570846ab7b4732389fa rdf:first sg:person.015620100105.09
59 rdf:rest N033eaeb36fdb44a7bd7ab9a3cec1e6ae
60 N2742310cb57b45a1a2f5c5e7c4faff96 rdf:first sg:person.0746041340.65
61 rdf:rest N924ef7440e634ee889e2e70a5216390a
62 N2b56687e2d404aa5bfb30e40e823e657 rdf:first sg:person.01152111734.09
63 rdf:rest N8e62d1811638481f95d4b5a6f73d59cc
64 N569d6c41363240ff9fd7530600d81542 rdf:first sg:person.0757541121.27
65 rdf:rest N21799051d7404570846ab7b4732389fa
66 N5ca8b132547140c99198a9ff14eed769 schema:name readcube_id
67 schema:value c12c77da7653d5747ef1139b8707361a28985ba0fef3adc5ff96e36faef3a19b
68 rdf:type schema:PropertyValue
69 N715c2e5fefa64b40b6c8bb791a12cc4b schema:issueNumber 3
70 rdf:type schema:PublicationIssue
71 N72a9410337f64f54a41db550d9961b97 rdf:first sg:person.01314355711.34
72 rdf:rest N95a26f044f544310b596d700f619cfca
73 N8e62d1811638481f95d4b5a6f73d59cc rdf:first Nf4e6b7f84dd140eb9e08563776a91494
74 rdf:rest N569d6c41363240ff9fd7530600d81542
75 N90e3bcbabaf640348b0551109f9787b1 schema:name doi
76 schema:value 10.1007/s40262-018-0700-3
77 rdf:type schema:PropertyValue
78 N924ef7440e634ee889e2e70a5216390a rdf:first sg:person.0614623553.04
79 rdf:rest N2b56687e2d404aa5bfb30e40e823e657
80 N9365cdad99c144ff8a7263a09dc564ce schema:name dimensions_id
81 schema:value pub.1106022094
82 rdf:type schema:PropertyValue
83 N95a26f044f544310b596d700f619cfca rdf:first sg:person.01367544315.00
84 rdf:rest rdf:nil
85 N9987eb37b2454bc7b6063e174032f0b0 schema:name Beijing Novartis Pharmaceuticals Corporation, Shanghai, China
86 rdf:type schema:Organization
87 N9c9a4d81561c4d7bbe03167e6c5d4ed7 schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 Nbab256c6dadf47ff93146ccec63eddc3 schema:volumeNumber 58
90 rdf:type schema:PublicationVolume
91 Nf4e6b7f84dd140eb9e08563776a91494 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
92 schema:familyName Rossato
93 schema:givenName Gianluca
94 rdf:type schema:Person
95 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
96 schema:name Medical and Health Sciences
97 rdf:type schema:DefinedTerm
98 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
99 schema:name Clinical Sciences
100 rdf:type schema:DefinedTerm
101 sg:journal.1085321 schema:issn 0312-5963
102 1179-1926
103 schema:name Clinical Pharmacokinetics
104 rdf:type schema:Periodical
105 sg:person.01152111734.09 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
106 schema:familyName Legangneux
107 schema:givenName Eric
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09
109 rdf:type schema:Person
110 sg:person.01314355711.34 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
111 schema:familyName Li
112 schema:givenName Wenkui
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314355711.34
114 rdf:type schema:Person
115 sg:person.01367544315.00 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
116 schema:familyName Shakeri-Nejad
117 schema:givenName Kasra
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00
119 rdf:type schema:Person
120 sg:person.015620100105.09 schema:affiliation N9987eb37b2454bc7b6063e174032f0b0
121 schema:familyName Su
122 schema:givenName Zhenzhong
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015620100105.09
124 rdf:type schema:Person
125 sg:person.0614623553.04 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
126 schema:familyName Ufer
127 schema:givenName Mike
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614623553.04
129 rdf:type schema:Person
130 sg:person.0615427741.32 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
131 schema:familyName Pal
132 schema:givenName Parasar
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615427741.32
134 rdf:type schema:Person
135 sg:person.0746041340.65 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
136 schema:familyName Gardin
137 schema:givenName Anne
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65
139 rdf:type schema:Person
140 sg:person.0757541121.27 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
141 schema:familyName Jin
142 schema:givenName Yi
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757541121.27
144 rdf:type schema:Person
145 sg:pub.10.1007/s00228-017-2404-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099922651
146 https://doi.org/10.1007/s00228-017-2404-2
147 rdf:type schema:CreativeWork
148 sg:pub.10.1016/j.clpt.2004.08.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033907987
149 https://doi.org/10.1016/j.clpt.2004.08.009
150 rdf:type schema:CreativeWork
151 sg:pub.10.1038/clpt.2008.302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015890832
152 https://doi.org/10.1038/clpt.2008.302
153 rdf:type schema:CreativeWork
154 https://app.dimensions.ai/details/publication/pub.1082883663 schema:CreativeWork
155 https://doi.org/10.1001/jamaneurol.2016.1451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011275377
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1002/jcph.561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023978690
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/j.clinthera.2015.09.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047057921
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/s0140-6736(18)30475-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101698897
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1016/s1474-4422(13)70102-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033439649
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1089/blr.2006.25.447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059238419
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1097/00008571-200309000-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060290069
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1097/fpc.0b013e3283349e84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060340789
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1111/j.1365-2125.2012.04400.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002553097
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1111/j.1476-5381.2012.02061.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043127544
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1111/nyas.12821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023965742
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1124/dmd.108.020396 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013227922
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1124/dmd.117.079574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103850020
180 rdf:type schema:CreativeWork
181 https://doi.org/10.2133/dmpk.dmpk-12-rv-085 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043672512
182 rdf:type schema:CreativeWork
183 https://doi.org/10.2217/pgs.10.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020935714
184 rdf:type schema:CreativeWork
185 https://doi.org/10.5414/cp202588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834626
186 rdf:type schema:CreativeWork
187 https://doi.org/10.5414/cp202608 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834636
188 rdf:type schema:CreativeWork
189 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
190 schema:name Novartis Institutes for Biomedical Research, East Hanover, NJ, USA
191 rdf:type schema:Organization
192 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
193 schema:name Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland
194 rdf:type schema:Organization
195 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
196 schema:name Novartis Healthcare Pvt. Ltd, Hyderabad, India
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...